Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | STK10 | O94804 | 2/20 | 0.47 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | TLK1 | Q9UKI8 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990917 | 0.83 | KMT2A (0.81) | MEN1KMT2APOLBSTK10SLK | |
| SCHEMBL26116957 | 0.81 | MEN1 (0.55) | MEN1KMT2APOLBHPGDEGFR | |
| SCHEMBL31296648 | 0.81 | MEN1 (0.55) | MEN1KMT2APOLBHPGDEGFR | |
| SCHEMBL31296647 | 0.81 | MEN1 (0.55) | MEN1KMT2APOLBHPGDEGFR | |
| SCHEMBL2772692 | 0.80 | POLB (0.49) | MEN1KMT2APOLBGSK3BGSK3A | |
| SCHEMBL2993822 | 0.80 | POLB (0.51) | MEN1KMT2APOLBLMNAHPGD | |
| SCHEMBL7785565 | 0.79 | KMT2A (0.60) | MEN1KMT2APOLBGSK3BGFER | |
| SCHEMBL30115032 | 0.79 | MEN1 (0.53) | MEN1KMT2APOLBSTK10SLK | |
| SCHEMBL7260357 | 0.77 | POLB (0.41) | MEN1KMT2APOLBSMN1; SMN2KDM4E | |
| SCHEMBL31296652 | 0.76 | RAPGEF4 (0.50) | MEN1KMT2APOLBLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPDRN PHSTMS D.S.S. (FR) | 2010-07-08 | — | — | US | claimed |
| EP-2178848-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2010-04-28 | — | — | EP | claimed |
| WO-2009034258-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2009-03-19 | — | — | WO | claimed |
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPDRN PHSTMS D.S.S. (FR) | 2010-07-08 | — | — | US | disclosed |
| EP-2178848-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009034258-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | CDC25B, CDC25A, CDC25C | MEN1 1932/4885KMT2A 1935/4885POLB 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.